8月14日，冠昊生物今日收盘17.65元，下跌3.45%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到167.79倍，总市值46.80亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，冠昊生物排 名第113位。 资金流向方面，8月14日，冠昊生物主力资金净流出1639.87万元，近5日总体呈流出状态，5日共流出 7166.14万元。 最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润1486.61万 元，同比3.30%，销售毛利率77.05%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13冠昊生物167.79170.708.4046.80亿行业平均 55.7651.784.92117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861. ...

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The main products include biological dura (spinal) membrane patches, chest repair membranes, sterile biological dressings, and corneal implants [2] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries classified as high-tech enterprises [2] Financial Performance - As of the first quarter of 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30% [2] - The gross profit margin stands at 77.05% [2] Market Position - The company's stock closed at 17.9 yuan, with a rolling price-to-earnings (PE) ratio of 170.17, significantly higher than the industry average of 54.79 and the median of 37.86 [1][3] - The total market capitalization is 4.746 billion yuan [1] Shareholder Information - As of July 31, 2025, the number of shareholders is 31,161, an increase of 562 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The main products include biological dura (spinal) membrane patches, B-type dura (spinal) membrane patches, thoracic repair membranes, sterile biological dressings, and other specialized medical materials [2] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries that are classified as high-tech enterprises [2] Financial Performance - For Q1 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] - The current stock price is 17.65 yuan, with a rolling price-to-earnings (PE) ratio of 167.79, significantly higher than the industry average of 53.93 and the median of 37.81 [1][3] Market Position - In terms of market capitalization, Guanhao Biological has a total market value of 4.68 billion yuan, ranking 113th in the medical device industry based on PE ratio [1] - The company has seen a net outflow of 17.35 million yuan in principal funds on August 6, but overall, there has been a net inflow of 61.34 million yuan over the past five days [1]

股东方面，截至2025年7月31日，冠昊生物股东户数31161户，较上次增加562户，户均持股市值35.28万 元，户均持股数量2.76万股。 冠昊生物科技股份有限公司的主营业务是致力于开发具有自主知识产权的新产品、新技术,将提升产品 质量、优化产品结构视为企业发展的核心驱动力,积极应对市场挑战,不断调整优化营销策略,积极提升品 牌影响力和市场占有率,不断推动公司核心业务生物材料、药业、细胞三大业务板块的协同快速发展。 公司的主要产品是生物型硬脑（脊）膜补片、B型硬脑（脊）膜补片、胸普外科修补膜、无菌生物护创 膜、艾瑞欧乳房补片、优得清脱细胞角膜植片。公司作为"国家知识产权优势企业"，其中商标"冠昊生 物""欣比克"纳入广东省重点商标保护名录。冠昊生物及下属子公司北昊研究院、中昊药业、武汉北度 均为高新技术企业；冠昊生物、北昊研究院、中昊药业均为广东省专精特新中小企业；冠昊科技园为国 家级科技企业孵化器、广州市中小企业服务站、优秀科技金融工作站、青年众创空间、粤港澳青少年交 流活动基地、黄埔区企业家服务中心工作站。 最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润 ...

冠昊生物科技股份有限公司的主营业务是致力于开发具有自主知识产权的新产品、新技术,将提升产品 质量、优化产品结构视为企业发展的核心驱动力,积极应对市场挑战,不断调整优化营销策略,积极提升品 牌影响力和市场占有率,不断推动公司核心业务生物材料、药业、细胞三大业务板块的协同快速发展。 公司的主要产品是生物型硬脑（脊）膜补片、B型硬脑（脊）膜补片、胸普外科修补膜、无菌生物护创 膜、艾瑞欧乳房补片、优得清脱细胞角膜植片。公司作为"国家知识产权优势企业"，其中商标"冠昊生 物""欣比克"纳入广东省重点商标保护名录。冠昊生物及下属子公司北昊研究院、中昊药业、武汉北度 均为高新技术企业；冠昊生物、北昊研究院、中昊药业均为广东省专精特新中小企业；冠昊科技园为国 家级科技企业孵化器、广州市中小企业服务站、优秀科技金融工作站、青年众创空间、粤港澳青少年交 流活动基地、黄埔区企业家服务中心工作站。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.46倍，行业中值37.74倍，冠昊生物排 名第111位。 股东方面，截至2025年7月18日，冠昊生物股东户数30599户，较上次减少1124户，户均持股市值35.28 万元，户 ...

Group 1 - The core business of the company focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as key drivers for growth [2] - The company reported a revenue of 94.79 million yuan for Q1 2025, representing a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] - As of July 18, 2025, the number of shareholders decreased to 30,599, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The company's current rolling PE ratio is 163.32, which is significantly higher than the industry average of 54.55 and the industry median of 37.54, ranking it 111th in the industry [1][3] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries that are classified as high-tech enterprises, contributing to its brand influence and market share [2] - The company operates in three main business segments: biomaterials, pharmaceuticals, and cell therapy, which are expected to develop synergistically [2]

最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润1486.61万 元，同比3.30%，销售毛利率77.05%。 7月22日，冠昊生物今日收盘16.71元，下跌2.34%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到158.86倍，总市值44.31亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.47倍，行业中值37.00倍，冠昊生物排 名第111位。 资金流向方面，7月22日，冠昊生物主力资金净流出1321.89万元，近5日总体呈流出状态，5日共流出 1092.10万元。 冠昊生物科技股份有限公司的主营业务是致力于开发具有自主知识产权的新产品、新技术,将提升产品 质量、优化产品结构视为企业发展的核心驱动力,积极应对市场挑战,不断调整优化营销策略,积极提升品 牌影响力和市场占有率,不断推动公司核心业务生物材料、药业、细胞三大业务板块的协同快速发展。 公司的主要产品是生物型硬脑（脊）膜补片、B型硬脑（脊）膜补片、胸普外科修补膜、无菌生物护创 膜、艾瑞欧乳房补片、优得清脱细胞角膜植片。公司作为"国家知识产权优势企业"，其中商标"冠昊生 ...

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The main products include biological dura (spinal) membrane patches, chest repair membranes, sterile biological dressings, and corneal implants [2] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries classified as high-tech enterprises [2] Financial Performance - For Q1 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up 3.30%, with a gross profit margin of 77.05% [2] - As of July 9, the company's stock closed at 15.91 yuan, down 1.49%, with a rolling PE ratio of 151.25 times and a total market capitalization of 4.219 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, positioning Guanhao Biological at 112th in the industry ranking [1][3] - The company's static PE ratio is 153.87 times, significantly higher than the industry average and median [3]

Group 1 - The core business of the company focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure [2] - The main products include biological dura (spinal) membrane patches, B-type dura (spinal) membrane patches, thoracic repair membranes, sterile biological dressings, and other specialized medical materials [2] - The company has achieved a revenue of 94.8 million yuan in Q1 2025, representing a year-on-year growth of 3.67%, with a net profit of 14.9 million yuan, also up by 3.30%, and a gross profit margin of 77.05% [2] Group 2 - As of June 5, the company's stock closed at 16.54 yuan, down 1.25%, with a rolling PE ratio of 157.24 times, and a total market capitalization of 4.386 billion yuan [1] - The average PE ratio in the medical device industry is 50.97 times, with a median of 36.67 times, placing the company at the 112th position in the industry ranking [1][3] - On June 5, the net outflow of main funds for the company was 19.1 million yuan, although there was an overall inflow of 32.2 million yuan over the past five days [1]

Group 1 - The core business of the company focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as key drivers for development [2] - The company has three main business segments: biomaterials, pharmaceuticals, and cell therapy, which are being developed in a coordinated manner [2] - The latest financial results for Q1 2025 show the company achieved operating revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] Group 2 - As of May 27, the company's stock closed at 13.85 yuan, with a rolling PE ratio of 131.67, marking a new low in 35 days, and a total market capitalization of 3.672 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device sector is 49.11, with a median of 35.89, placing the company at the 110th position in the industry [1][3] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries classified as high-tech enterprises, contributing to its brand influence and market share [2]